The Plant by Westleaf Labs will have a throughput capacity of up to 65,000 kilograms per annum in Phase I. The plant is now entering the final stages of the Health Canada licensing process.
The completion of the plant positions the company to meet the expected new demand for cannabis derivative products anticipated to be coming to market in December of this year.
Phase I is a 15,000 square foot extraction, processing and product formulation facility with a designed throughput capacity of up to 65,000 kgs of cannabis feedstock per year. The facility has additional 45,000 square feet available for expansion.
The plant will produce Westleaf’s suite of brands, Loon, Backstage and General Admission, in addition to providing contract extraction and processing services, and white-label products for third parties.
“This is a significant milestone for Westleaf, marking our transition from construction to operations and execution on our plan to build a brand focused vertically integrated cannabis company,” Scott Hurd CEO stated.
Westleaf expects to receive a standard processing license for the plant as early as the third quarter of 2019.
“Once licensed, this facility will produce the current suite of legal cannabis derivative products, and as we move towards additional cannabis product legalization in the fourth quarter, we will expand our product lines to include vapes, edibles and other derivative cannabis products.”
Westleaf anticipates the next phase of cannabis legalization in Canada, which is expected to come later this year, will see a significant change in consumption habits among Canadians.